Samuel Joseph McGrath

Dr. Samuel Joseph McGrath


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2025 in JACC: Advances
Verified
Journal Article
Open access
SMSamuel Joseph McGrath
Samuel Joseph McGrath
BABashir Alaour
Bashir Alaour
TKThomas Kampourakis
Thomas Kampourakis
MMMichael Marber
Michael Marber
Cardiac troponin is the gold standard biomarker for the diagnosis of acute myocardial infarction (AMI). Development of high-sensitivity troponin platforms has revolutionized triage of chest pain patients, but specificity for type 1 AMI remains a clinical limitation. Consequently, differentiating type 1 AMI from other forms of myocardial injury is a common conundrum, heightened by the risks associated invasive coronary angiography. The troponin complex is a dynamic structure comprising of 3 subunits which variably fragment prior to measurement in the blood. Documenting the fragmentation patterns of cardiac troponin may help identify the cause of myocardial injury. This review explores the biology underlying troponin fragmentation and summarizes multiple lines of evidence that it can improve the specificity for diagnosis of type 1 AMI.

1 April 2026 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Closed access
MRMuhamad Abd Razak
Muhamad Abd Razak
GVGeorge Vamvakas
George Vamvakas
MMMichael McGarvey
Michael McGarvey
SMSamuel Joseph McGrath
Samuel Joseph McGrath
Krishnaraj Sinhji RathodKrishnaraj Sinhji Rathod
Krishnaraj Sinhji Rathod
NPNilesh Pareek
Nilesh Pareek
BACKGROUND: The purpose of this study was to prospectively validate the MIRACLE 2 score in the GLOBAL-MIRACLE registry, a multicenter, international, prospective registry of patients admitted with resuscitated out-of-hospital cardiac arrest of presumed cardiac cause. METHODS: From January 1, 2022 to May 31, 2023, 770 patients were recruited from 11 centers across 5 countries. The primary end point was poor neurological outcome (Cerebral Performance Category 3–5) at hospital discharge. Model discrimination was assessed by the area under the receiver operating characteristic curve. We compared the discriminatory performance of the MIRACLE 2 score against Cardiac Arrest Hospital Prognosis, out-of-hospital cardiac arrest, Target Temperature Management, NULL-PLEASE, C-GRAPH, and rCAST. RESULTS: The primary end point occurred in 395 (51.2%) patients. The MIRACLE 2 score had an area under the curve of 0.861 (95% CI, 0.835–0.887). A MIRACLE 2 score ≤2 had a negative predictive value of 87.8%, while a score of ≥7 had a positive predictive value of 98.3%. The MIRACLE 2 score had equal performance to the TTM risk tool ( P =0.12) but better discriminatory performance than other risk tools ( P <0.0001). The MIRACLE 2 score showed good performance in those with ST-segment–elevation myocardial infarction (0.851 [95% CI, 0.816–0.886]) and without ST-segment–elevation myocardial infarction (0.873 [95% CI, 0.834–0.912]) and in those with cardiogenic shock (0.832 [95% CI, 0.789–0.875]) and without cardiogenic shock (0.853 [95% CI, 0.810–0.895]). CONCLUSIONS: The MIRACLE 2 score is a practical risk tool that shows excellent discrimination performance for poor neurological outcome after presumed cardiac cause out-of-hospital cardiac arrest, including based on hemodynamic status and admission 12-lead ECG. Early stratification of out-of-hospital cardiac arrest patients using the MIRACLE 2 score should be evaluated in future randomized controlled trials.

12 December 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AGAaron Goldberg
Aaron Goldberg
SMSamuel Joseph McGrath
Samuel Joseph McGrath
MMMichael Marber
Michael Marber
Laboratory-based high-sensitivity cardiac troponin testing has been the pillar for emergency stratification of suspected acute coronary syndrome for well over a decade. Point-of-care troponin assays achieving the requisite analytical sensitivity have recently been developed and could accelerate such assessment. This review summarises the latest assays and describes their potential diverse clinical utility in the emergency department, community healthcare, pre-hospital, and other hospital settings. It outlines the current clinical data but also highlights the evidence gap, particularly the need for clinical trials using whole blood, that must be addressed for safe and successful implementation of point-of-care troponin analysis into daily practice. Additionally, how point-of-care troponin testing can be coupled with advances in biosensor technology, cardiovascular screening, and triage algorithms is discussed.

23 July 2025 in JACC: Case Reports
Verified
Journal Article
Open access
SMSamuel Joseph McGrath
Samuel Joseph McGrath
TBTimothy Bagnall
Timothy Bagnall
NPNicholas Pegge
Nicholas Pegge
DHDavid Hildick-Smith
David Hildick-Smith
Lost guidewires during central venous catheterization are rare but serious, requiring prompt removal to reduce morbidity and mortality. A 58-year-old woman presented with a pulsating back mass and a spontaneous bruise under her left clavicle. More than 10 years ago, a 0.035-inch guidewire had been lost in her circulation, and retrieval attempts had failed. Computed tomography scan revealed a fragmented guidewire that had crossed into the arterial circulation through a patent foramen ovale and extended through the anterior mediastinum. After a discussion among the heart team, the decision was made to remove the wire percutaneously. This case highlights the risks of guidewire loss and the successful use of advanced catheter techniques for complex wire retrieval. Iatrogenic guidewire loss is associated with significant risk of morbidity and mortality, and the guidewire must be removed. A fragmented wire can be removed percutaneously by forming a free loop with an additional wire. If wire embolization is recognized during central venous catheter insertion, several bedside techniques can be attempted to rapidly correct the complication.

14 November 2025 in Expert Review of Cardiovascular Therapy
Verified
Journal Article
Open access
SMSamuel Joseph McGrath
Samuel Joseph McGrath
BABashir Alaour
Bashir Alaour
MMMichael Marber
Michael Marber
Cardiac Troponin (cTn) is fundamental to the diagnosis of myocardial injury. High sensitivity cTn assays have transformed acute cardiac care by shifting the focus toward rapid rule-out of myocardial infarction, allowing the early identification and safe discharge of low-risk patients. However, cTn proteins and their assays have limitations. The review summarizes cTn as a biomarker of myocardial injury, high-sensitivity cTn assay performance, and their combined impact on chest pain pathways. It explores Cardiac Myosin-Binding Protein C (cMyC) and discusses the evidence behind its use as an alternative biomarker. Studies available on Pubmed were analyzed using keywords cTn, cMyC, myocardial infarction, triage, chest pain and assay. The second half of this review explores the proteolysis of both these biomarkers, and how this information could be used in clinical practice. Both hs-cTn and hs-cMyC assays have shown equivalent diagnostic performance in the rule-out of myocardial infarction. Unfortunately, both are also plagued by the similar liabilities: decreased specificity for Type 1 AMI, and an inability to distinguish between types of myocardial injury. Proteolysis of each biomarker differs according to underlying pathology. Novel assays that quantify distinct forms could enhance patient triage.

10 June 2025 in Interventional Cardiology: Reviews, Research, Resources
Verified
Journal Article
Open access
PDF file
SMSamuel Joseph McGrath
Samuel Joseph McGrath
HMHolly Morgan
Holly Morgan
DMDouglas Muir
Douglas Muir
DHDavid Hildick-Smith
David Hildick-Smith
Background: Interventional cardiology (IC) is a competitive and oversubscribed subspecialty. The UK cardiology programme is currently in a state of transition of curricula, and concerns have arisen about the impact of this change on the standard of training. This study aimed to provide a snapshot of UK IC training at present. Methods: A 68-question survey was disseminated through the British Cardiovascular Interventional Society mailing list in November 2023 to all UK intervention trainees across both curricula. Questions included procedural numbers, exposure to adjunct techniques and confidence in the transition to consultancy. Results: The survey was completed by 60 participants, providing a response rate of 38% for training grades. A total of 87% of participants were men, and 78% remained on the 2010 curriculum. For the 2010 curriculum trainees, the median number of first-operator percutaneous coronary intervention was 101–200 in their first year. Confidence levels were higher for radial (98%) than femoral (62%) access. A total of 83% felt comfortable or confident using intravascular lithotripsy (83%) compared with 23% for rotational atherectomy. Comfort was higher with intravascular ultrasound (82%) compared with optical coherence tomography (53%). Half felt unprepared for consultancy, citing insufficient procedural experience. To address this, 65% plan to extend training with a fellowship year. Overall, 72% rated the programme as excellent or good, and 10% as poor. Conclusion: While many trainees report a positive experience with UK IC training, several areas need improvement, including procedural volume and requirement for extended training. Moving forward, it will be crucial to monitor the impact of the 2022 curriculum on IC training.